Optimizing the Path from Pre-Clinical to Clinical Development
Timely progression of a drug candidate into clinical trials is critical for pharmaceutical companies seeking to bring new products to the market. Streamlining chemistry, manufacturing, and controls (CMC) development can help accelerate this process, as well as help yield better success as the drug product moves through the early phase of clinical studies.
Photometer Calibration: Calibration Error Due to Errors in Gravimetric Standard of Measurement
May 28th 2025This technical note explores the sources of error in gravimetric measurements used for aerosol photometer calibration, emphasizing the impact of discrepancies in aerosol properties, temporal instability, and flawed experimental procedures. It supports the two-point calibration practice to minimize errors, particularly at lower concentrations, and recommends measures such as improved aerosol systems and automation to enhance calibration accuracy. The findings aim to ensure reliable photometer performance for critical applications.
Photometer Calibration: The Case for Two-Point Calibration and Multi-Point Verification
May 28th 2025This technical note discusses the rationale for using two-point calibration and multi-point verification in the calibration of aerosol photometers. It explains the theoretical basis for the linear relationship between photometric response and aerosol mass concentration, highlights practical challenges with multi-point calibration, and advocates for two-point calibration to minimize errors. The combination of two-point calibration and multi-point verification ensures the accuracy and performance of the photometer in critical applications.
Cooperating With Our Customers Across the US
May 13th 2025Highlighting the importance for our clients to prepurchase multi-year maintenance contracts, in order to avoid their machines breaking or stopping to work suddenly and unexpectedly, to minimize the risk of interrupted production and emergency maintenance costs.
Large-Scale LNP Process Conversions: The many hurdles of LNP scale-up and what to consider
May 12th 2025Lipid nanoparticle (LNP) formulation development begins on a small scale, often with homemade or benchtop setups, using syringe pumps and easily accessible micro-mixing systems. Once a promising formulation has been identified, the next step is to transition to standardized large-scale impingement mixing systems, such as the high flow T-mixing pumps that were used to produce the COVID-19 vaccines (Sealy 2021). Formulators need to consider a number of factors when scaling up novel LNP systems. These include flow rates that affect LNP particles, solvent removal, risk factors when changing equipment, and the impact of tangential flow filtration sensitivity. In this technical note, we discuss these factors and what needs to be considered when developing a cost- and time efficient large-scale process.
